KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions to authors
- Article processing charge
- e-submission
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
Review
- Basic Research
- Application of Animal Models in Diabetic Cardiomyopathy
- Wang-Soo Lee, Jaetaek Kim
- Diabetes Metab J. 2021;45(2):129-145. Published online March 25, 2021
- DOI: https://doi.org/10.4093/dmj.2020.0285
- 9,195 View
- 332 Download
- 9 Web of Science
- 14 Crossref
-
Graphical Abstract
Abstract
PDF
PubReader 
ePub - Diabetic heart disease is a growing and important public health risk. Apart from the risk of coronary artery disease or hypertension, diabetes mellitus (DM) is a well-known risk factor for heart failure in the form of diabetic cardiomyopathy (DiaCM). Currently, DiaCM is defined as myocardial dysfunction in patients with DM in the absence of coronary artery disease and hypertension. The underlying pathomechanism of DiaCM is partially understood, but accumulating evidence suggests that metabolic derangements, oxidative stress, increased myocardial fibrosis and hypertrophy, inflammation, enhanced apoptosis, impaired intracellular calcium handling, activation of the renin-angiotensin-aldosterone system, mitochondrial dysfunction, and dysregulation of microRNAs, among other factors, are involved. Numerous animal models have been used to investigate the pathomechanisms of DiaCM. Despite some limitations, animal models for DiaCM have greatly advanced our understanding of pathomechanisms and have helped in the development of successful disease management strategies. In this review, we summarize the current pathomechanisms of DiaCM and provide animal models for DiaCM according to its pathomechanisms, which may contribute to broadening our understanding of the underlying mechanisms and facilitating the identification of possible new therapeutic targets.
-
Citations
Citations to this article as recorded by
- Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model
Georgică Târtea, Aurel Popa-Wagner, Veronica Sfredel, Smaranda Ioana Mitran, Alexandra Oltea Dan, Anca-Maria Țucă, Alexandra Nicoleta Preda, Victor Raicea, Eugen Țieranu, Dragoș Cozma, Radu Vătășescu
International Journal of Molecular Sciences.2024; 25(4): 2118. CrossRef - Mitochondrial energy metabolism in diabetic cardiomyopathy: Physiological adaption, pathogenesis, and therapeutic targets
Wanlin Ye, Kun Han, Maodi Xie, Sheyu Li, Guo Chen, Yanyan Wang, Tao Li
Chinese Medical Journal.2024; 137(8): 936. CrossRef - Liraglutide Attenuates Diabetic Cardiomyopathy via the ILK/PI3K/AKT/PTEN Signaling Pathway in Rats with Streptozotocin-Induced Type 2 Diabetes Mellitus
Shatha M. Alobaid, Rahaf M. Alshahrani, Asma S. Alonazi, Nawal M. Alrasheed, Maha A. Alamin, Tahani K. Alshammari, Anfal F. Bin Dayel, Doaa M. Elnagar, Rana R. Alotaibi, Lama A. Almuthnabi, Dalia H. Almasud, Shahad E. Al-Ammar, Shahad O. Almadhi, Reema A.
Pharmaceuticals.2024; 17(3): 374. CrossRef - An Overview of Diabetic Cardiomyopathy
Abdul Quaiyoom, Ranjeet Kumar
Current Diabetes Reviews.2024;[Epub] CrossRef - Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
International Journal of Heart Failure.2023; 5(1): 1. CrossRef - Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement
Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 10. CrossRef - Machine learning for spatial stratification of progressive cardiovascular dysfunction in a murine model of type 2 diabetes mellitus
Andrya J. Durr, Anna S. Korol, Quincy A. Hathaway, Amina Kunovac, Andrew D. Taylor, Saira Rizwan, Mark V. Pinti, John M. Hollander, Yoshihiro Fukumoto
PLOS ONE.2023; 18(5): e0285512. CrossRef - Hyperglycemic memory in diabetic cardiomyopathy
Jiabing Zhan, Chen Chen, Dao Wen Wang, Huaping Li
Frontiers of Medicine.2022; 16(1): 25. CrossRef - Murine Models of Obesity
Tânia Martins, Catarina Castro-Ribeiro, Sílvia Lemos, Tiago Ferreira, Elisabete Nascimento-Gonçalves, Eduardo Rosa, Paula Alexandra Oliveira, Luís Miguel Antunes
Obesities.2022; 2(2): 127. CrossRef - The Role of Mitochondria in Metabolic Syndrome–Associated Cardiomyopathy
Jiayu Li, Jingye Li, Yijun Chen, Wenyu Hu, Xuhe Gong, Hui Qiu, Hui Chen, Yanguo Xin, Hongwei Li, Tao Li
Oxidative Medicine and Cellular Longevity.2022; 2022: 1. CrossRef - Guidelines on models of diabetic heart disease
Lisa C. Heather, Anne D. Hafstad, Ganesh V. Halade, Romain Harmancey, Kimberley M. Mellor, Paras K. Mishra, Erin E. Mulvihill, Miranda Nabben, Michinari Nakamura, Oliver J. Rider, Matthieu Ruiz, Adam R. Wende, John R. Ussher
American Journal of Physiology-Heart and Circulatory Physiology.2022; 323(1): H176. CrossRef - Extracellular vesicle therapy for non-ischemic heart failure: A systematic review of preclinical studies
Ramana Vaka, Sophie Van Remortel, Valentina Ly, Darryl R. Davis
Extracellular Vesicle.2022; 1: 100009. CrossRef - Effect of a Six-week Endurance Exercise Program and Empagliflozin Consumption on Some Structural and Functional Indices of the Heart in Male Diabetic Rats
Eftekhar Mohammadi, Mohammad Fathi, Farzaneh Chehel Cheraghi, Afshin Nazari
journal of ilam university of medical sciences.2022; 30(3): 1. CrossRef - Cardiac Phosphodiesterases Are Differentially Increased in Diabetic Cardiomyopathy
Rita Hanna, Wared Nour-Eldine, Youakim Saliba, Carole Dagher-Hamalian, Pia Hachem, Pamela Abou-Khalil, Delphine Mika, Audrey Varin, Magali Samia El Hayek, Laëtitia Pereira, Nassim Farès, Grégoire Vandecasteele, Aniella Abi-Gerges
Life Sciences.2021; 283: 119857. CrossRef
- Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model
First
Prev
